News & Events

BD Medical – Ophthalmic Systems, a unit of BD (Becton, Dickinson and Company), announced today the European launch of BD OcuSeal Liquid Ocular Bandage, a fully synthetic protective barrier designed to provide comfort for post-surgical, post-traumatic, and non-traumatic ocular conditions.  This product has European CE Mark approval, and BD intends to initiate registration in other countries including the United States.

BD OcuSeal Liquid Ocular Bandage is designed to help reduce the need for sutures and reduce complications typically associated with surgical incisions, including infection and patient discomfort.  It is intended for direct application on corneal, conjunctival, and scleral surfaces.

BD OcuSeal Liquid Ocular Bandage consists of a synthetic hydrogel that is applied directly to the ocular surface as a liquid, using a special brush applicator.  The hydrogel is activated by mixing two separate components.  This product is engineered to form a low-profile, smooth, soft and transparent protective barrier film on the ocular surface.

“With the addition of BD OcuSeal Liquid Ocular Bandage to the BD family of single-use ophthalmic products, BD continues to demonstrate its commitment to improving patient safety during ophthalmic surgery,” says Doug Lawrence, Vice President and General Manager, BD Medical – Ophthalmic Systems.  BD has an exclusive license from Hyperbranch Medical Technology to market BD OcuSeal Liquid Ocular Bandage for use in ophthalmology.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents.  The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines.  BD's capabilities are instrumental in combating many of the world's most pressing diseases.  Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world.  The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.  For more information, please visit www.bd.com